HMGB1 and neoplasm: In subgroup analysis, for 76 patients with tumor >5 cm, the 1, 3, 5-year overall survival for patients with HMGB1 high expression was 75.1%, 36.6%, 26.6% respectively, and 74.3%, 62.4%, 52.5% respectively for patients with HMGB1 low expression (p = 0.031), the corresponding disease-free survival was 34.5%, 14.6%, 14.6% respectively, and 52.9%, 40.0%, 32.0% respectively (p = 0.012, Figure 4).